DE60131537D1 - Nitrosierte und nitrosylierte taxane, zubereitungen und methoden der verwendung - Google Patents
Nitrosierte und nitrosylierte taxane, zubereitungen und methoden der verwendungInfo
- Publication number
- DE60131537D1 DE60131537D1 DE60131537T DE60131537T DE60131537D1 DE 60131537 D1 DE60131537 D1 DE 60131537D1 DE 60131537 T DE60131537 T DE 60131537T DE 60131537 T DE60131537 T DE 60131537T DE 60131537 D1 DE60131537 D1 DE 60131537D1
- Authority
- DE
- Germany
- Prior art keywords
- nitrosed
- preparations
- methods
- nitrosylated taxanes
- nitrosylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Surgery (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21329400P | 2000-06-22 | 2000-06-22 | |
US213294P | 2000-06-22 | ||
US22609000P | 2000-08-18 | 2000-08-18 | |
US226090P | 2000-08-18 | ||
PCT/US2001/019939 WO2001098286A1 (en) | 2000-06-22 | 2001-06-22 | Nitrosated and nitrosylated taxanes, compositions and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60131537D1 true DE60131537D1 (de) | 2008-01-03 |
DE60131537T2 DE60131537T2 (de) | 2008-10-23 |
Family
ID=26907932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60131537T Expired - Fee Related DE60131537T2 (de) | 2000-06-22 | 2001-06-22 | Nitrosierte und nitrosylierte taxane, zubereitungen und methoden der verwendung |
Country Status (7)
Country | Link |
---|---|
US (2) | US6656966B2 (de) |
EP (1) | EP1301500B1 (de) |
JP (1) | JP2004501143A (de) |
AU (2) | AU2001270070B2 (de) |
CA (1) | CA2410632A1 (de) |
DE (1) | DE60131537T2 (de) |
WO (1) | WO2001098286A1 (de) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1118325B2 (de) * | 1993-07-29 | 2010-01-06 | The United States of America, represented by the Secretary, Department of Health and Human Services | Verwendung von Paclitaxel und seinen Derivaten zur Herstellung eines Medikaments für die Behandlung von Restenose |
US20030040790A1 (en) | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
US7967855B2 (en) | 1998-07-27 | 2011-06-28 | Icon Interventional Systems, Inc. | Coated medical device |
US8070796B2 (en) | 1998-07-27 | 2011-12-06 | Icon Interventional Systems, Inc. | Thrombosis inhibiting graft |
EP1278547B1 (de) | 2000-04-26 | 2004-11-03 | Cellegy Pharmaceuticals, Inc | Formulierungen und verfahren zur verwendung von stickstoffmonoxid mimetika gegen einen malignen zellphänotyp |
US7678391B2 (en) * | 2000-04-26 | 2010-03-16 | Queen's University At Kingston | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
US20050142217A1 (en) * | 2000-04-26 | 2005-06-30 | Adams Michael A. | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
WO2002026139A1 (en) † | 2000-09-29 | 2002-04-04 | Cordis Corporation | Coated medical devices |
US20040110691A1 (en) * | 2001-11-13 | 2004-06-10 | Stamler Jonathan S. | Thiol reactive agents as a therapeutic modality |
US6627602B2 (en) * | 2001-11-13 | 2003-09-30 | Duke University | Preventing desensitization of receptors |
AU2006252204B2 (en) * | 2001-12-06 | 2010-07-08 | Duke University | Prevention of Flap Necrosis in Plastic Surgery |
AU2002254931A1 (en) * | 2002-03-07 | 2003-09-16 | Universite Catholique De Louvain | Method for diagnosing and treating predisposition for accelerated autosomal dominant polycystic kidney disease |
US20030203915A1 (en) * | 2002-04-05 | 2003-10-30 | Xinqin Fang | Nitric oxide donors, compositions and methods of use related applications |
CA2483214C (en) | 2002-04-24 | 2012-05-29 | Insense Limited | Wound dressings comprising hydrated hydrogels and enzymes |
US20040038947A1 (en) | 2002-06-14 | 2004-02-26 | The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services | Method of treating ischemia/reperfusion injury with nitroxyl donors |
US8016881B2 (en) | 2002-07-31 | 2011-09-13 | Icon Interventional Systems, Inc. | Sutures and surgical staples for anastamoses, wound closures, and surgical closures |
US6936639B2 (en) * | 2002-08-21 | 2005-08-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitroxyl progenitors in the treatment of heart failure |
EP1534340B1 (de) | 2002-09-06 | 2011-11-16 | Cerulean Pharma Inc. | Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel |
US20050004098A1 (en) * | 2003-03-20 | 2005-01-06 | Britten Nancy Jean | Dispersible formulation of an anti-inflammatory agent |
US20040214753A1 (en) * | 2003-03-20 | 2004-10-28 | Britten Nancy Jean | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
JP2006520779A (ja) * | 2003-03-20 | 2006-09-14 | ファルマシア コーポレイション | 抗炎症薬の分散性処方物 |
US20050009931A1 (en) * | 2003-03-20 | 2005-01-13 | Britten Nancy Jean | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
ITMI20030743A1 (it) * | 2003-04-11 | 2004-10-12 | Biopeg Ltd | Derivati di polietilenglicoli che rilasciano ossido nitrico. |
US20050038498A1 (en) * | 2003-04-17 | 2005-02-17 | Nanosys, Inc. | Medical device applications of nanostructured surfaces |
US7972616B2 (en) * | 2003-04-17 | 2011-07-05 | Nanosys, Inc. | Medical device applications of nanostructured surfaces |
US7803574B2 (en) * | 2003-05-05 | 2010-09-28 | Nanosys, Inc. | Medical device applications of nanostructured surfaces |
GB0313217D0 (en) | 2003-06-09 | 2003-07-16 | Insense Ltd | Improvements in or relating to skin dressings |
JP2007504136A (ja) * | 2003-08-28 | 2007-03-01 | ニトロメッド インコーポレーティッド | ニトロソ化およびニトロシル化利尿化合物、組成物、ならびに使用方法 |
JP2007516294A (ja) * | 2003-12-23 | 2007-06-21 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 炎症性の疾患または症状の予防および治療のための方法および組成物 |
US7211108B2 (en) | 2004-01-23 | 2007-05-01 | Icon Medical Corp. | Vascular grafts with amphiphilic block copolymer coatings |
EP1766405A1 (de) * | 2004-05-21 | 2007-03-28 | MDS Inc. doing Business Through Its MDS Pharma Services Division | Verfahren zur quantifizierung der zellbindungseigenschaften einer medizinischen vorrichtung |
PL1750862T3 (pl) * | 2004-06-04 | 2011-06-30 | Teva Pharma | Kompozycja farmaceutyczna zawierająca irbesartan |
US20060039950A1 (en) * | 2004-08-23 | 2006-02-23 | Zhengrong Zhou | Multi-functional biocompatible coatings for intravascular devices |
WO2006024492A2 (en) * | 2004-08-30 | 2006-03-09 | Interstitial Therapeutics | Medical implant provided with inhibitors of atp synthesis |
US9107899B2 (en) | 2005-03-03 | 2015-08-18 | Icon Medical Corporation | Metal alloys for medical devices |
WO2006110197A2 (en) | 2005-03-03 | 2006-10-19 | Icon Medical Corp. | Polymer biodegradable medical device |
US7540995B2 (en) | 2005-03-03 | 2009-06-02 | Icon Medical Corp. | Process for forming an improved metal alloy stent |
US20060222592A1 (en) * | 2005-04-05 | 2006-10-05 | Clemens Burda | Nanoparticles and methods of manufacturing nanoparticles for electronic and non-electronic applications |
EP1909779A1 (de) * | 2005-06-23 | 2008-04-16 | Johns Hopkins University | Thiol-empfindliche positiv-inotrope |
US20080241208A1 (en) * | 2005-06-30 | 2008-10-02 | Charles Shanley | Methods, Compositions and Devices For Promoting Anglogenesis |
WO2007026337A2 (en) * | 2005-09-02 | 2007-03-08 | The Procter & Gamble Company | Methods for retail measurement of skin moisture content |
US7566308B2 (en) * | 2005-10-13 | 2009-07-28 | Cardiac Pacemakers, Inc. | Method and apparatus for pulmonary artery pressure signal isolation |
US20090048667A1 (en) * | 2005-11-16 | 2009-02-19 | Tokai University Educational System | Controlled Drug-Release Composition and Drug-Releasable Medical Device |
US20080051702A1 (en) * | 2006-08-24 | 2008-02-28 | Herrmann Robert A | Therapeutic agent delivery for the treatment of asthma via implantable and insertable medical devices |
JP5602432B2 (ja) * | 2007-01-11 | 2014-10-08 | ロバート ラマール ジュニア ビョーク | 経皮的冠動脈インターベンション用の多剤溶出冠動脈ステント |
US9339593B2 (en) * | 2007-01-11 | 2016-05-17 | Robert L. Bjork, JR. | Drug-eluting coronary artery stent coated with anti-platelet-derived growth factor antibodies overlaying extracellular matrix proteins with an outer coating of anti-inflammatory (calcineurin inhibitor) and/or anti-proliferatives |
JP2010516625A (ja) | 2007-01-24 | 2010-05-20 | インサート セラピューティクス, インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
KR100904207B1 (ko) | 2007-06-01 | 2009-06-25 | (주) 태웅메디칼 | 스텐트용 약물 방출 코팅제, 그의 제조방법 및 이 코팅제로 코팅된 약물 방출 스텐트 |
JP2010539245A (ja) | 2007-09-14 | 2010-12-16 | 日東電工株式会社 | 薬物担体 |
US8319002B2 (en) * | 2007-12-06 | 2012-11-27 | Nanosys, Inc. | Nanostructure-enhanced platelet binding and hemostatic structures |
CN101883545B (zh) | 2007-12-06 | 2013-08-07 | 纳诺西斯有限公司 | 可再吸收的纳米增强型止血结构和绷带材料 |
WO2010005687A1 (en) * | 2008-06-12 | 2010-01-14 | University Of Alabama Huntsville | Compositions comprising nitric oxide or nitric oxide donors for the treatment of neurodegenerative diseases or trauma |
CA2731503A1 (en) * | 2008-07-21 | 2010-01-28 | Osiris Therapeutics, Inc. | Taxane compounds for treating eye disease |
US8888840B2 (en) * | 2009-05-20 | 2014-11-18 | Boston Scientific Scimed, Inc. | Drug eluting medical implant |
US8992601B2 (en) | 2009-05-20 | 2015-03-31 | 480 Biomedical, Inc. | Medical implants |
AU2010249558A1 (en) | 2009-05-20 | 2011-12-08 | Arsenal Medical, Inc. | Medical implant |
US9265633B2 (en) | 2009-05-20 | 2016-02-23 | 480 Biomedical, Inc. | Drug-eluting medical implants |
US9309347B2 (en) | 2009-05-20 | 2016-04-12 | Biomedical, Inc. | Bioresorbable thermoset polyester/urethane elastomers |
US20110319987A1 (en) | 2009-05-20 | 2011-12-29 | Arsenal Medical | Medical implant |
US8372133B2 (en) | 2009-10-05 | 2013-02-12 | 480 Biomedical, Inc. | Polymeric implant delivery system |
WO2011063339A1 (en) * | 2009-11-23 | 2011-05-26 | Cardioxyl Pharmaceuticals, Inc. | Nitroxyl donors for the treatment of pulmonary hypertension |
AU2010328230B2 (en) * | 2009-12-07 | 2016-06-02 | Cardioxyl Pharmaceuticals, Inc. | Bis-acylated hydroxylamine derivatives |
EP2509941B1 (de) * | 2009-12-07 | 2019-01-23 | The Johns Hopkins University | N-acelyerte hydroxylaminderivate und o-acylierte hydroxylaminderivate |
EP2519467B1 (de) | 2009-12-28 | 2020-09-09 | Colorado State University Research Foundation | Modulare biokompatible materialien für medizinische vorrichtungen und verwendung |
US8398916B2 (en) | 2010-03-04 | 2013-03-19 | Icon Medical Corp. | Method for forming a tubular medical device |
WO2012116177A2 (en) * | 2011-02-24 | 2012-08-30 | Colorado State University Research Foundation | Materials for modulating biological responses and methods of making |
US20130196946A1 (en) * | 2012-01-31 | 2013-08-01 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
US9884943B2 (en) | 2012-09-21 | 2018-02-06 | Michigan Technological University | No-releasing polymers and uses thereof |
WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
EP3160397A4 (de) | 2014-06-24 | 2018-03-21 | Icon Medical Corp. | Verbesserte metalllegierungen für medizinische vorrichtungen |
RU2018113280A (ru) | 2015-09-16 | 2019-10-16 | ДиЭфБи СОРИА, ЭлЭлСи | Доставка наночастиц лекарственного средства и способы их использования |
US11766506B2 (en) | 2016-03-04 | 2023-09-26 | Mirus Llc | Stent device for spinal fusion |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
WO2018170196A1 (en) | 2017-03-15 | 2018-09-20 | Dfb Soria, Llc | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes |
WO2018191415A1 (en) | 2017-04-11 | 2018-10-18 | Colorado State University Research Foundation | Functionalization of metal-organic frameworks |
US11497726B2 (en) | 2018-03-16 | 2022-11-15 | Dfb Soria, Ll. | Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using nanoparticles of taxanes |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666884A (en) | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
US4885173A (en) | 1985-05-01 | 1989-12-05 | University Of Utah | Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities |
US5157049A (en) | 1988-03-07 | 1992-10-20 | The United States Of America As Represented By The Department Of Health & Human Services | Method of treating cancers sensitive to treatment with water soluble derivatives of taxol |
US4900719A (en) | 1988-08-05 | 1990-02-13 | The Ohio State University | Nitrosothiols as hypotensive agents |
US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
EP0533816B1 (de) | 1990-06-15 | 1995-06-14 | Cortrak Medical, Inc. | Vorrichtung zur abgabe von medikamenten |
US6028205A (en) | 1991-09-23 | 2000-02-22 | Florida State University | C2 tricyclic taxanes |
US5998656A (en) | 1991-09-23 | 1999-12-07 | Florida State University | C10 tricyclic taxanes |
US5284864A (en) * | 1991-09-23 | 1994-02-08 | Florida State University | Butenyl substituted taxanes and pharmaceutical compositions containing them |
US5990325A (en) | 1993-03-05 | 1999-11-23 | Florida State University | Process for the preparation of 9-desoxotaxol, 9-desoxobaccatin III and analogs thereof |
US5399726A (en) | 1993-01-29 | 1995-03-21 | Florida State University | Process for the preparation of baccatin III analogs bearing new C2 and C4 functional groups |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5272171A (en) | 1992-02-13 | 1993-12-21 | Bristol-Myers Squibb Company | Phosphonooxy and carbonate derivatives of taxol |
US5407816A (en) | 1992-02-20 | 1995-04-18 | Phyton Catalytic, Inc. | Enhanced production of taxol and taxanes by cell cultures of taxus species |
US5278192A (en) | 1992-07-02 | 1994-01-11 | The Research Foundation Of State University Of New York | Method of vasodilator therapy for treating a patient with a condition |
FR2698871B1 (fr) | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
IL108316A (en) | 1993-01-15 | 2006-10-31 | Univ Florida State | History of C-10 Texan and pharmaceuticals containing them |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
DE69433297T2 (de) * | 1993-02-05 | 2004-10-21 | Bryn Mawr College Bryn Mawr | Synthese von taxol, seinen analogen und intermediaten mit variablen a-ring seitenketten |
US5464650A (en) | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5852058A (en) | 1993-06-11 | 1998-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
US5861168A (en) | 1993-06-11 | 1999-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
US5945452A (en) | 1993-06-11 | 1999-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity |
EP0703909B1 (de) | 1993-06-11 | 2000-04-26 | PHARMACIA & UPJOHN COMPANY | Delta 6, 7-taxolen, antineoplastische verwendung und diese enthaltende pharmazeutische zusammenstellungen |
US5428070A (en) | 1993-06-11 | 1995-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity |
US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
EP1118325B2 (de) | 1993-07-29 | 2010-01-06 | The United States of America, represented by the Secretary, Department of Health and Human Services | Verwendung von Paclitaxel und seinen Derivaten zur Herstellung eines Medikaments für die Behandlung von Restenose |
CA2129288C (en) | 1993-08-17 | 2000-05-16 | Jerzy Golik | Phosphonooxymethyl esters of taxane derivatives |
IL127598A (en) | 1994-01-28 | 2003-04-10 | Upjohn Co | Process for preparing isotaxol analogs |
US5482925A (en) | 1994-03-17 | 1996-01-09 | Comedicus Incorporated | Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents |
NZ288802A (en) | 1994-06-28 | 1998-05-27 | Upjohn Co | Ether taxol derivatives, preparation and pharmaceutical compositions thereof |
US5629433A (en) | 1994-07-18 | 1997-05-13 | Hauser, Inc. | Selective process for the deacylation and deacetylation of taxol and taxanes |
AU3725895A (en) | 1994-10-06 | 1996-05-02 | New York University | Administration of a 27-hydroxycholesterol or prodrug thereof as an anti-cancer agent |
US6100411A (en) | 1994-10-28 | 2000-08-08 | The Research Foundation Of State University Of New York | Taxoid anti-tumor agents and pharmaceutical compositions thereof |
EP0738265A1 (de) | 1994-11-04 | 1996-10-23 | PHARMACIA S.p.A. | Taxan derivate |
GB9423868D0 (en) | 1994-11-25 | 1995-01-11 | Wellcome Found | Compounds for use in medicine |
EP0799051B1 (de) | 1994-12-12 | 2005-07-27 | Omeros Corporation | Bespüllungslösung und deren verwendung zur perioperativen hemmung von schmerzen, entzündungen und spasmen an einer wunde |
US5679807A (en) | 1995-01-30 | 1997-10-21 | Hauser, Inc. | Preparation of taxol and docetaxel through primary amines |
US6063407A (en) | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
US6231600B1 (en) | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
US5665077A (en) | 1995-04-24 | 1997-09-09 | Nitrosci Pharmaceuticals Llc | Nitric oxide-releasing nitroso compositions and methods and intravascular devices for using them to prevent restenosis |
US5780653A (en) * | 1995-06-07 | 1998-07-14 | Vivorx Pharmaceuticals, Inc. | Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers |
CA2178541C (en) | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
US5703117A (en) | 1995-09-12 | 1997-12-30 | The Liposome Company, Inc. | Hydrolysis-promoting hydrophobic taxane derivatives |
CA2231837A1 (en) * | 1995-09-13 | 1997-03-20 | Florida State University | Radiosensitizing taxanes and their pharmaceutical preparations |
US6177456B1 (en) | 1995-10-02 | 2001-01-23 | Xechem International, Inc. | Monohalocephalomannines having anticancer and antileukemic activity and method of preparation therefor |
WO1997019938A1 (es) | 1995-11-29 | 1997-06-05 | Consejo Superior Investigaciones Cientificas | Derivados fluorescentes de paclitaxel y docetaxel con actividad antineoplasica, metodo para obtenerlos y sus aplicaciones |
US5760072A (en) | 1995-12-29 | 1998-06-02 | Pharmachemie B.V. | Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy |
US5951458A (en) | 1996-02-29 | 1999-09-14 | Scimed Life Systems, Inc. | Local application of oxidizing agents to prevent restenosis |
US5688977A (en) | 1996-02-29 | 1997-11-18 | Napro Biotherapeutics, Inc. | Method for docetaxel synthesis |
CA2250295C (en) | 1996-03-12 | 2008-12-30 | Pg-Txl Company L.P. | Water soluble paclitaxel prodrugs |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US5919815A (en) | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
ATE196844T1 (de) | 1996-05-22 | 2000-10-15 | Protarga Inc | Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten |
WO1998000419A1 (en) | 1996-07-02 | 1998-01-08 | Bristol-Myers Squibb Company | Ortho-ester analogs of paclitaxel |
US5797887A (en) | 1996-08-27 | 1998-08-25 | Novovasc Llc | Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation |
IT1295694B1 (it) | 1996-11-14 | 1999-05-27 | Nicox Sa | Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica |
US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
US5977386A (en) | 1996-12-24 | 1999-11-02 | Bristol-Myers Squibb Company | 6-thio-substituted paclitaxels |
US5902822A (en) | 1997-02-28 | 1999-05-11 | Bristol-Myers Squibb Company | 7-methylthiooxomethyl and 7-methylthiodioxomethyl paclitaxels |
US5912264A (en) | 1997-03-03 | 1999-06-15 | Bristol-Myers Squibb Company | 6-halo-or nitrate-substituted paclitaxels |
US6017935A (en) | 1997-04-24 | 2000-01-25 | Bristol-Myers Squibb Company | 7-sulfur substituted paclitaxels |
DE19718339A1 (de) | 1997-04-30 | 1998-11-12 | Schering Ag | Polymer beschichtete Stents, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe |
KR100428634B1 (ko) | 1997-07-11 | 2004-11-03 | 주식회사 코오롱 | 진균을 이용한 탁솔의 제조 |
JPH1192468A (ja) | 1997-09-17 | 1999-04-06 | Yakult Honsha Co Ltd | 新規なタキサン誘導体 |
US6358536B1 (en) | 1997-10-15 | 2002-03-19 | Thomas Jefferson University | Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
US5994444A (en) | 1997-10-16 | 1999-11-30 | Medtronic, Inc. | Polymeric material that releases nitric oxide |
US20020164374A1 (en) | 1997-10-29 | 2002-11-07 | John Jackson | Polymeric systems for drug delivery and uses thereof |
US6150537A (en) | 1997-12-12 | 2000-11-21 | Emory University | Methods for the esterification of alcohols and compounds useful therefor as potential anticancer agents |
WO1999055317A2 (en) | 1998-04-30 | 1999-11-04 | The Johns Hopkins University | Treatment of advanced decompensated heart failure with nitric oxide donors |
US6448417B1 (en) | 1998-05-01 | 2002-09-10 | Napro Biotherapeutics, Inc. | Methods and useful intermediates for paclitaxel synthesis from C-7, C-10 di-cbz 10-deacetylbaccatin III |
US5981564A (en) | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
US5916913A (en) | 1998-08-03 | 1999-06-29 | Joseph; Hazel L. | Inhibition of wound contraction with paclitaxel, colchicine and penicillamine |
ATE218560T1 (de) | 1998-08-21 | 2002-06-15 | Pharmachemie Bv | Wasserlösliche ähnliche verbindungen und medicament-vorstufe von paclitaxel |
US6017948A (en) | 1998-10-30 | 2000-01-25 | Supergen, Inc. | Water-miscible pharmaceutical compositions |
US6071952A (en) | 1998-12-02 | 2000-06-06 | Mylan Pharmaceuticals, Inc. | Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents |
IT1311923B1 (it) | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
IT1311921B1 (it) | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
IT1311924B1 (it) | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
EP1207811A4 (de) | 1999-08-04 | 2007-03-07 | Bard Inc C R | Stickoxid-freisetzende medizinische artikel |
IT1314184B1 (it) | 1999-08-12 | 2002-12-06 | Nicox Sa | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo |
-
2001
- 2001-06-22 WO PCT/US2001/019939 patent/WO2001098286A1/en active IP Right Grant
- 2001-06-22 AU AU2001270070A patent/AU2001270070B2/en not_active Ceased
- 2001-06-22 JP JP2002504242A patent/JP2004501143A/ja active Pending
- 2001-06-22 DE DE60131537T patent/DE60131537T2/de not_active Expired - Fee Related
- 2001-06-22 CA CA002410632A patent/CA2410632A1/en not_active Abandoned
- 2001-06-22 EP EP01948610A patent/EP1301500B1/de not_active Expired - Lifetime
- 2001-06-22 AU AU7007001A patent/AU7007001A/xx active Pending
- 2001-06-22 US US09/886,494 patent/US6656966B2/en not_active Expired - Fee Related
-
2003
- 2003-10-14 US US10/682,923 patent/US6869973B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2001098286A1 (en) | 2001-12-27 |
US20040087510A1 (en) | 2004-05-06 |
EP1301500A4 (de) | 2004-03-31 |
EP1301500B1 (de) | 2007-11-21 |
AU7007001A (en) | 2002-01-02 |
CA2410632A1 (en) | 2001-12-27 |
DE60131537T2 (de) | 2008-10-23 |
EP1301500A1 (de) | 2003-04-16 |
JP2004501143A (ja) | 2004-01-15 |
US20020010146A1 (en) | 2002-01-24 |
US6656966B2 (en) | 2003-12-02 |
US6869973B2 (en) | 2005-03-22 |
AU2001270070B2 (en) | 2006-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60131537D1 (de) | Nitrosierte und nitrosylierte taxane, zubereitungen und methoden der verwendung | |
DE60223841D1 (de) | Medizinische verwendung von gsk3-hemmenden oxindolderivaten | |
DE60236767D1 (de) | Medizinische Verwendung eines TetrahydrotriazoloÄ4,3-aÜpyrazins | |
DE50213336D1 (de) | Substituierte 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre verwendung | |
NO20034925L (no) | Cykliske N-aroylaminer | |
DE50212455D1 (de) | Verwendung von Dimerdiolen | |
DK1668001T3 (da) | Substituerede heteroarylbenzofuransyrer | |
NO20044916L (no) | Preparater av sulfinylacetamid | |
DE60126814D1 (de) | Inhalation von stickoxid | |
CY1107485T1 (el) | 3-θειομεθυλπυραζoλες ως παρασιτοκτoνα | |
DE60211106D1 (de) | Zusammensetzung zur Oxidationsfärbung von Keratinfasern | |
ATE428695T1 (de) | Spirocyclische 3-phenyl-3-substituierte-4- ketolaktame und -laktone | |
ATE277045T1 (de) | Salze von bicyclischen, n-acylierten imidazo-3- aminen und imidazo-5-aminen | |
DE60024652D1 (de) | Unkonjugiertes cyklisches polyencopolymer, kautschukzusammensetzung und verwendung | |
DE50103536D1 (de) | Verwendung von kationischen Zubereitungen | |
DE602004015504D1 (de) | Von injektionspräparaten | |
TR200402030T4 (tr) | İkame edilen I-aminobutan-3-ol-türevleri | |
NO20042613L (no) | Ny anvendelse for behandling av gastroosofagial refluks | |
ATE395917T1 (de) | Kombination von docetaxel mit flavopiridol | |
DE60217870D1 (de) | Verwendung von 2- 5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze | |
DE60007360T2 (de) | Amorphe modifikation von torasemid | |
NO20023697D0 (no) | Cykliske heksapeptidderivater | |
DE50203087D1 (de) | Medizinische bandelektrode | |
DE50103099D1 (de) | Verwendung von kationischen Zubereitungen | |
NO20033919D0 (no) | Ny anvendelse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |